Burleson, Texas — Burleson, Texas

Burleson, Texas is a clinical research site located in Burleson, Texas, United States 76028.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Burleson, Texas has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO), Diabetic Macular Edema (DME).

Sponsors: EyeBiotech Ltd..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Burleson

Browse all research sites in Texas · View every site in Burleson

• Texas Health Huguley Hospital South
• Star Vision Research
• Star Retina
• The Center for Cancer and Blood Disorders
• Helios Clinical Research
• Ventavia Research Group
• Pfizer Investigational Site
• The Center for Cancer and Blood Disorders-Burleson
• Cedar Health Research, LLC
• Star Vision Consultants
• Fort Worth Heart

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Burleson, Texas?

Burleson, Texas has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Burleson, Texas conducted?

Burleson, Texas has 2 clinical trials on record, with 2 currently active. Their work covers Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO), Diabetic Macular Edema (DME).

Is Burleson, Texas accredited by Crixeo Clinical Trials?

Burleson, Texas has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Burleson, Texas?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.